Recent Updates
Recently added Catalysts
RDY Neutral Sentiment Score: 60/100

SECURITIES AND EXCHANGE COMMISSION

Key Takeaway: Dr. Reddy's Laboratories Limited submitted a report to the Securities and Exchange Commission under the Securities Exchange Act of 1934. The report includes information regarding the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. market, which occurred on January 27, 2023. The document confirms the company's compliance with reporting requirements and includes details about the submission and the registrant's principal executive office in Hyderabad, India.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Reddy's Labs launched Difluprednate Ophthalmic Emulsion in the U.S.
  • The report complies with SEC requirements, indicating organizational diligence.

Full Press Release Details

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-15182
REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If "Yes" is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
Exhibit Number Description of Exhibits
99.1 Press Release dated January 27, 2023 regarding "Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market".
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY'S LABORATORIES LIMITED (Registrant)
Date: January 27, 2023 By: /s/ K Randhir Singh
Name: K Randhir Singh
Title: Company Secretary

Frequently Asked Questions

What is the address of Dr. Reddy's Laboratories Limited?

The address is 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India.

What is Form 6-K used for?

Form 6-K is submitted by foreign private issuers to report documents required under local laws.

When was the press release about Difluprednate issued?

The press release regarding Difluprednate was issued on January 27, 2023.

Who signed the report for Dr. Reddy's Laboratories?

The report was signed by K Randhir Singh, the Company Secretary.

What does Regulation S-T Rule 101 allow?

It allows submission of Form 6-K in paper under specific conditions for annual reports.

Last updated: Jan 27, 2023